FOLH1

(redirected from Prostate-Specific Membrane Antigen)
Also found in: Acronyms.

FOLH1

A gene on chromosome 11p11.2 that encodes folate hydrolase 1, which has both folate hydrolase (FH) and N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity. It acts as an FH in the intestine and is required for the uptake of folate; in the brain, it modulates excitatory neurotransmission by hydrolysing the neuropeptide N-aceylaspartylglutamate (NAAG), releasing glutamate. It is highly expressed in the prostate.
Mentioned in ?
References in periodicals archive ?
89]Zr-Df-IAB2M targets prostate-specific membrane antigen (PSMA), a transmembrane protein highly expressed in the majority of prostate cancer, both localized and metastatic disease.
Upregulation of prostate-specific membrane antigen after androgendeprivation therapy.
2006, "Successful in vivo tumor targeting of prostate-specific membrane antigen with a highly efficient J591/PEI/DNA molecular conjugate," Gene Ther.
Because of their high sensitivity, RT-PCR assays incorporating prostate cell-derived mRNA markers such as PSA, prostate-specific membrane antigen, and hK2 have been used for the detection of PC cells.
Researchers at UC Irvine have developed a new diagnostic that uses urine for prostate cancer screening with the Prostate-Specific Membrane Antigen.
Several reverse transcriptase-polymerase chain reaction (RT-PCR) protocols are able to amplify the mRNAs encoding prostate-specific antigen (PSA) or prostate-specific membrane antigen (PSMA) in blood [1], lymph nodes [3], or bone marrow [4].
Nasdaq: PGNX) today reported positive preliminary data from an ongoing phase 1 study of PSMA ADC, an antibody-drug conjugate (ADC) designed to selectively deliver chemotherapy to cells that express prostate-specific membrane antigen (PSMA).
IAB2M is a monoclonal antibody fragment targeting prostate-specific membrane antigen (PSMA).
Nasdaq: PGNX) today presented the design and rationale of an ongoing phase 1 trial of its prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) therapy at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Prostate-specific membrane antigen (PSMA) is a transmembrane protein commonly found on the surface of late-stage and metastatic prostate cancer and a well-known imaging biomarker for staging and monitoring therapy.
Abstract #198: Heterogeneity of prostate-specific membrane antigen (PSMA) expression in classic and apoptotic circulating tumor cells (CTC) in metastatic castration-resistant prostate cancer (mCRPC).

Full browser ?